Vanguard Global Advisers
ORIC icon

Vanguard Global Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Vanguard Global Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Sell
28,297
-11,558
-29% -$105K ﹤0.01% 2319
2026
Q1 		$505K Buy
+39,855
New +$452K ﹤0.01% 2040

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's ORIC Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Oric Pharmaceuticals (ORIC) stake by 29% in Q2 2026, selling an estimated $105K and leaving 28,297 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Vanguard Global Advisers first reported a position in ORIC in Q1 2026 and has held it in 2 quarters since. The position peaked at $505K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Vanguard Global Advisers held 28,297 shares of Oric Pharmaceuticals worth $306K as of Q2 2026.
  • Vanguard Global Advisers sold 11,558 Oric Pharmaceuticals shares in Q2 2026, an estimated $105K.
  • Oric Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2319 holding.
  • Vanguard Global Advisers first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Oric Pharmaceuticals position peaked at $505K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.